Výsledky vyhledávání

Akademický článek

Managing Pain in Patients With Cancer: The Chinese Good Pain Management Experience

Autor: Shi-Ying Yu, Jie-Jun Wang, Yu-guang Huang, Bing Hu, Kun Wang, Ping Ping Li, Yi-Long Wu, He-Long Zhang, Li Zhang, Qing-Yuan Zhang, Shu-Kui Qin

Publikováno v: Journal of Global Oncology, Vol 3, Iss 5, Pp 583-595 (2017)

Purpose: The number of cancer cases in China has increased rapidly from 2.1 million in 2000 to 4.3 million in 2015. As a consequence, pain management as an integral part of cancer treatment became an important health care issue. In March 2011, the Go

Externí odkaz: https://doaj.org/article/7df45a3a76974f9789de7cf46fbdc155

Zobrazit plný text záznamu

Akademický článek

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib

Autor: Yan Yang, MD, PhD, Shu-Kui Qin, MD, PhD, Jian Zhu, MD, Rui Wang, MD, Yu-Mei Li, MD, Zong-Yu Xie, MD, Qiong Wu, MD, PhD

Publikováno v: Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 1, Iss 1, Pp 111-116 (2017)

The ALK gene fusion has been identified as a new driver gene in non–small cell lung cancer (NSCLC). It includes the EML4-ALK rearrangement as a recurring event that renders the tumor sensitive to ALK tyrosine kinase inhibitor crizotinib. In additio

Externí odkaz: https://doaj.org/article/a60bb26110cf41a9b232fc491974caea

Zobrazit plný text záznamu

Supplementary Data. from HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib

Supplementary Data: List of TRIO investigators, Supplementary Materials and Methods, Supplementary Results, Supplementary Discussion, Supplementary References, Supplementary Tables, and Supplementary Figures.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dcefbe9e663b9232264cc987f8bc9cb
https://doi.org/10.1158/1535-7163.22508224.v1

Zobrazit plný text záznamu

A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma

Autor: Yang, Zhang, Fan, Luo, Yu-Xiang, Ma, Qian-Wen, Liu, Yun-Peng, Yang, Wen-Feng, Fang, Yan, Huang, Ting, Zhou, Jin, Li, Hong-Ming, Pan, Lei, Yang, Shu-Kui, Qin, Hong-Yun, Zhao, Li, Zhang

Publikováno v: The Oncologist. 27:e453-e462

Background Lucitanib is a novel multi-target inhibitor of FGFR1-3, VEGFR 1-3, and PDGFR α/β. Here, we evaluated the safety, tolerability, and preliminary efficacy of lucitanib in recurrent and metastatic nasopharyngeal carcinoma (RM-NPC). Methods P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b87d1428a9e6e4fc9cd1b703c5791fb
https://doi.org/10.1093/oncolo/oyab076

Zobrazit plný text záznamu

Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients

Publikováno v: Cancer. 128(5)

KEYNOTE-063 (NCT03019588) investigated pembrolizumab versus paclitaxel as second-line therapy in Asian patients with advanced programmed death ligand 1 (PD-L1)-positive (combined positive score ≥1) gastric/gastroesophageal junction (GEJ) cancer.Thi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c3b53adf624b8e7cbda01133c61b279
https://pubmed.ncbi.nlm.nih.gov/34878659

Zobrazit plný text záznamu

A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix

Autor: Jue Zhang, Shu-Kui Qin, Chao Chen, Yu Zhang, Xianwen Luo, Zixiong Li, Xiufeng Liu

Publikováno v: OncoTargets and Therapy. 12:5805-5811

Objective Although advances have been made in the clinical and therapeutic management of women with cervical cancer, the best treatment for patients with metastatic or recurrent cervical cancer is still undefined. Apatinib, a novel inhibitor of vascu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::39f491daf14d287d326dca54fd21f070
https://doi.org/10.2147/ott.s212536

Zobrazit plný text záznamu

Plný text ve formátu HTML

A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of Patient-Derived Tumor Xenograft (PDTX)

Autor: Yuan Cheng, Shu-kui Qin, Jin Li, Guang-hai Dai, Bai-yong Shen, Jie-er Shen, Yi Ba, Xin-bo Wang, Ye Xu, Lin Zhou, Ke-feng Ding, Yan-ru Qin, Shu-jun Yang, Yan-ping Zhu

Background: Establish patient-derived tumor xenograft (PDTX) from advanced GICs and assess the clinical value and applicability of PDTX for the treatment of advanced GICs. Method: Patients with advanced GICs were enrolled in a registered multi-center

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1cf6da904bd18d2b0b5b880ce222eabb
https://doi.org/10.21203/rs.3.rs-212867/v1

Zobrazit plný text záznamu

Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report

Autor: Yuan Cheng, Shu kui Qin, Juan Zhang, Hai qing Hua

Publikováno v: OncoTargets and Therapy. 11:5957-5962

Olaparib is an oral poly ADP-ribose polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2)-associated breast and ovarian cancers. There is no report about treatment with olaparib in BRCA1/2-mutated intrahepatic cholangiocarcinomas.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1bdf4a251b6b7d553c0bafd85148f1b8
https://doi.org/10.2147/ott.s176914

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání